LONDON, December 14 /PRNewswire/ - The Benefits of Anastrozole (Arimidex(R)) Over Tamoxifen at Preventing Breast Cancer Recurrence Improve Over Time - Up to Four Years After Treatment Ends New data from ATAC(x), one of the world s largest and longest-running studies in postmenopausal women with hormone receptor positive (HR+), early breast cance
Application based on results from the TROPION-Breast01 phase 3 trial
Additional BLA under review in the U.S. for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan for patients with.
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer expected in early April 2024 Median progression free survival of.